Roche Diagnostics and Burjeel Holdings Partner to Innovate Healthcare through Digital Diagnostics

Roche Diagnostics Middle East FZCO and Burjeel Holdings have signed a Memorandum of Understanding (MOU) to collaborate on digitizing and innovating laboratory processes in the healthcare industry. Both companies aim to improve patient experience and outcomes providing accurate, reliable, and efficient services.

As “Digital Lab Incubation Partners,” Roche Diagnostics and Burjeel Holdings will combine their expertise and technical support to develop digital solutions for precise diagnosis and personalized treatment pathways. This partnership will generate valuable knowledge and insights through structured reports, use cases, and whitepapers.

The General Manager at Roche Diagnostics Middle East FZCO, Guido Sander, expressed excitement about the collaboration, stating that the partnership aligns with their mission of creating a healthier future through innovation. The CEO of Burjeel Holdings, Mr. John Sunil, also emphasized their dedication to excellence and innovation in healthcare.

Both organizations share a commitment to elevate healthcare standards in the region leveraging their collective strengths. This partnership signifies a joint effort to bring about positive transformations in the healthcare landscape.

Roche Diagnostics is a global leader in the field, founded in 1896 in Switzerland. They are the world’s largest biotechnology company and a pioneer in personalized healthcare. Roche offers comprehensive pharmaceutical and diagnostic expertise in the Middle East.

Burjeel Holdings, founded in 2007, is one of the leading private healthcare services providers in the MENA region. With a network of hospitals, medical centers, pharmacies, and allied services, they provide the highest standard of patient care.

Source: Roche Diagnostics Middle East FZCO, Burjeel Holdings